Dear Natalie,

Southwark PCT's response to the following HTA is as follows;

Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women

i) whether you consider that all of the relevant evidence has been taken into account
   Response: Yes

ii) whether you consider that the summaries of clinical and cost effectiveness are reasonable interpretations of the evidence and that the preliminary views on the resource impact and implications for the NHS are appropriate
   Response: Yes

iii) whether you consider that the provisional recommendations of the Appraisal Committee are sound and constitute a suitable basis for the preparation of guidance to the NHS.
   Response: Yes

Regards